Evidence map›Paper›PMID 29248757›Full record

ArticleVirology2018

Envelope glycoproteins sampling states 2/3 are susceptible to ADCC by sera from HIV-1-infected individuals.

Jérémie Prévost, Jonathan Richard, Shilei Ding, Beatriz Pacheco, Roxanne Charlebois, Beatrice H Hahn, Daniel E Kaufmann, Andrés Finzi

Open access · greenAbstract read
In one paragraph

Article in Virology, 2018. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 40 papers.

0numbers the graph read from it
0cells of the map it votes in
40citing papers in PubMed
3.1field-weighted citation impact, top 8% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

40 citing papers in PubMed, 52 citations in OpenAlex.

  1. Article
  2. Review
  3. Article
  4. Article
  5. Article
  6. Article
  7. Article
  8. Article
  9. Article
  10. Article
  11. Article
  12. Article
  13. Article
  14. Article
  15. Article
  16. Article
  17. Article
  18. Article
  19. Article
  20. Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

8 authors at 4 institutions in 2 countries.

Jérémie PrévostCentre de Recherche du CHUM, QC, Canada H2X 0A9; Department of Microbiology, Infectiology and Immunology, Université de Montréal, Montreal, QC, Canada H2X 0A9.
Jonathan RichardCentre de Recherche du CHUM, QC, Canada H2X 0A9; Department of Microbiology, Infectiology and Immunology, Université de Montréal, Montreal, QC, Canada H2X 0A9.
Shilei DingCentre de Recherche du CHUM, QC, Canada H2X 0A9; Department of Microbiology, Infectiology and Immunology, Université de Montréal, Montreal, QC, Canada H2X 0A9.
Beatriz PachecoCentre de Recherche du CHUM, QC, Canada H2X 0A9.
Roxanne CharleboisCentre de Recherche du CHUM, QC, Canada H2X 0A9.
Beatrice H HahnDepartments of Medicine and Microbiology, Perelman School of Medicine, University of Pennsylvania, Philadelphia, PA 19104-6076, USA.
Daniel E KaufmannCentre de Recherche du CHUM, QC, Canada H2X 0A9; Department of Medicine, Université de Montréal, Montreal, QC, Canada H3C 3T5; Center for HIV/AIDS Vaccine Immunology and Immunogen Discovery, The Scripps Research Institute, La Jolla, CA 92037, USA.
Andrés FinziCentre de Recherche du CHUM, QC, Canada H2X 0A9; Department of Microbiology, Infectiology and Immunology, Université de Montréal, Montreal, QC, Canada H2X 0A9; Department of Microbiology and Immunology, McGill University, Montreal, QC, Canada H3A 2B4. Electronic address: andres.finzi@umontreal.ca.
Centre Hospitalier de l’Université de Montréal · CAMcGill University Health Centre · CAScripps Research Institute · USUniversity of Pennsylvania · US

Funding

Virus biology scientific research support componentUM1AI100645 · NIAID · DUKE UNIVERSITY · PI KEPLER, THOMAS B · 2012 to 2018
$204.7M
Support Component D/Vaccine Discovery, Concept to ClinicUM1AI100663 · NIAID · SCRIPPS RESEARCH INSTITUTE, THE · PI BAROUCH, DAN H. · 2012 to 2018
$131.5M
Virus and Antibody Gene Sequencing CoreP01AI131251 · NIAID · UNIVERSITY OF PENNSYLVANIA · PI Kevin Wiehe · 2017 to 2026
$40.7M
Unlocking Envelope: A New Strategy for a Functional Cure Through Antibody-Dependent Cell-Mediated CytotoxicityR01AI129769 · NIAID · UNIVERSITY OF MARYLAND BALTIMORE · PI PAZGIER, MARZENA ELZBIETA · 2017 to 2021
$2.3M
CIHR 352417NIAID NIH HHS P01 AI131251NIAID NIH HHS R01 AI129769NIAID NIH HHS UM1 AI100645NIAID NIH HHS UM1 AI100663
6 · The paper itself

Abstract

Recent analysis of HIV-1 envelope glycoproteins (Env) dynamics showed that the unliganded Env trimer can potentially sample three conformations: a metastable "closed" conformation (State 1), an "open" CD4-bound conformation (State 3), and an intermediate "partially open" conformation (State 2). HIV-1 evolved several mechanisms to avoid "opening" its Env in order to evade immune responses such as antibody-dependent cellular cytotoxicity (ADCC), which preferentially targets Envs in the CD4-bound conformation on the surface of infected cells. Here we took advantage of a well-characterized single-residue change in the gp120 trimer association domain to modify Env conformation and evaluate its impact on ADCC responses. We found that cells infected with viruses expressing Env stabilized in States 2/3 become highly susceptible to ADCC responses by sera from HIV-1-infected individuals. Our results indicate that the conformations spontaneously sampled by the Env trimer at the surface of infected cells has a significant impact on ADCC responses.

Indexed as

Antibody-Dependent Cell CytotoxicityCD4 Antigensenv Gene Products, Human Immunodeficiency VirusHIV-1HIV AntibodiesHIV InfectionsHumansSerumCD4 Antigensenv Gene Products, Human Immunodeficiency VirusHIV AntibodiesADCCCD4Envelope glycoproteinsHIV-1Non-neutralizing antibodiesStates 2/3

Identifiers

PMID29248757
PMCPMC5843759
OpenAlexW2775272863

What Socratic holds

Textmetadata
LicenceTDM
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the Socratic graph.